Zerbib, F; Bruley des Varannes, S; Roman, S; Tutuian, R; Galmiche, J-P; Mion, F; Tack, J; Malfertheiner, P; Keywood, C (2011). Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 33(8), pp. 911-21. Oxford: Wiley-Blackwell 10.1111/j.1365-2036.2011.04596.x
Full text not available from this repository. (Request a copy)ADX10059, a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator, has been shown to reduce gastro-oesophageal reflux events and oesophageal acid exposure in patients with gastro-oesophageal reflux disease (GERD) and healthy subjects.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology |
UniBE Contributor: |
Tutuian, Radu |
ISSN: |
0269-2813 |
Publisher: |
Wiley-Blackwell |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:23 |
Last Modified: |
05 Dec 2022 14:06 |
Publisher DOI: |
10.1111/j.1365-2036.2011.04596.x |
PubMed ID: |
21320138 |
Web of Science ID: |
000288515800006 |
URI: |
https://boris.unibe.ch/id/eprint/7761 (FactScience: 213087) |
Actions (login required)
 |
Edit item |